51940-64-8

Usage

Uses

Used in Organic Synthesis:
Ethyl 2,4-dichloropyrimidine-5-carboxylate is used as a key intermediate for the synthesis of various organic compounds. Its unique chemical structure allows for further functionalization and the creation of a wide range of products with diverse applications.
Used in Agrochemical Industry:
In the agrochemical industry, ethyl 2,4-dichloropyrimidine-5-carboxylate is used as a starting material for the development of new pesticides and other agricultural chemicals. Its reactivity and structural features make it a valuable component in the design and synthesis of effective and targeted agrochemicals.
Used in Pharmaceutical Industry:
Ethyl 2,4-dichloropyrimidine-5-carboxylate is employed as an important intermediate in the pharmaceutical industry for the synthesis of various drugs. Its chemical properties enable the development of new therapeutic agents with potential applications in treating a range of medical conditions.
Used in Dyestuff Industry:
In the dyestuff industry, ethyl 2,4-dichloropyrimidine-5-carboxylate is used as a raw material for the production of different types of dyes. Its structural characteristics contribute to the development of novel dyes with improved properties, such as enhanced color strength and stability.

Synthesis Reference(s)

Journal of the American Chemical Society, 64, p. 794, 1942 DOI: 10.1021/ja01256a016

InChI:InChI=1/C7H6Cl2N2O2/c1-2-13-6(12)4-3-10-7(9)11-5(4)8/h3H,2H2,1H3

Upstream product

• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 144-55-8 sodium hydrogencarbonate 
• 1428760-91-1 ethyl 2,4-dioxohexahydropyrimidine-5-carboxylate 
• 92264-75-0 2,4-dioxohexahydropyrimidine-5-carboxylic acid 
• 23945-44-0 2,4-dihydroxypyrimidine-5-carboxylic acid 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 64-17-5 ethanol 
• 2972-52-3 2,4-dichloropyrimidine-5-carbonyl chloride 
• 28485-17-8 5-carbethoxyuracil 
• 28485-17-8 5-carbethoxyuracil 

Downstream Products

• 65754-04-3 6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid 
• 55996-27-5 2-ethoxy-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid ethyl ester 
• 4595-61-3 pyrimidine-5-carboxylic acid 
• 71406-78-5 ethyl 4-amino-2-chloropyrimidine-5-carboxylate 
• 863028-78-8 ethyl 2-chloro-4-(3-isopropylanilino)pyrimidine-5-carboxylate 
• 227449-13-0 ethyl 2-chloro-4-(3-methoxyanilino)pyrimidine-5-carboxylate 
• 227449-11-8 ethyl 2-chloro-4-(3-trifluoromethylanilino)pyrimidine-5-carboxylate 
• 227449-05-0 ethyl 2-chloro-4-(4-methylanilino)pyrimidine-5-carboxylate 
• 280581-48-8 4-phenylamino-2-chloropyrimidine-5-carboxylic acid ethyl ester 
• 227449-09-4 ethyl 2-chloro-4-(3-methylanilino)pyrimidine-5-carboxylate 
• 863028-77-7 ethyl 2-chloro-4-(3-ethylanilino)pyrimidine-5-carboxylate 
• 227449-12-9 ethyl 2-chloro-4-(3-cyanoanilino)pyrimidine-5-carboxylate 
• 227449-10-7 ethyl 2-chloro-4-(2-methylanilino)pyrimidine-5-carboxylate 
• 227449-16-3 ethyl 4-(3-bromoanilino)-2-chloropyrimidine-5-carboxylate 

Relevant academic research and scientific papers

Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors

Macrocycles have attracted significant attention in drug discovery recently. In fact, a few de novo designed macrocyclic kinase inhibitors are currently in clinical trials with good potency and selectivity for their intended target. In this study, we successfully engaged a structure-based drug design approach to discover macrocyclic pyrimidines as potent Mer tyrosine kinase (MerTK)-specific inhibitors. An enzyme-linked immunosorbent assay (ELISA) in 384-well format was employed to evaluate the inhibitory activity of macrocycles in a cell-based assay assessing tyrosine phosphorylation of MerTK. Through structure–activity relationship (SAR) studies, analogue 11 [UNC2541; (S)-7-amino-N-(4-fluorobenzyl)-8-oxo-2,9,16-triaza-1(2,4)-pyrimidinacyclohexadecaphane-1-carboxamide] was identified as a potent and MerTK-specific inhibitor that exhibits sub-micromolar inhibitory activity in the cell-based ELISA. In addition, an X-ray structure of MerTK protein in complex with 11 was resolved to show that these macrocycles bind in the MerTK ATP pocket.

Atorvastatin that non-preparation method

The invention relates to a preparation method of avanafil and a new compound provided in a preparation process. According to the method, 5-uracil carboxylic acid or an ester thereof is taken as the raw material, and the avanafil meeting the clinical requirements can be synthesized at a relatively cost; besides, the preparation method is simple and convenient to operate, mild in reaction conditions, high in yield, low in cost, environmentally friendly and suitable for industrial large-scale production of the avanafil.

THERAPUETIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY

Uses of pyrimidines with anti-Mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK -/- tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

PHARMACEUTICAL COMPOUNDS

The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

Compounds of Formula I or II: are described, along with pharmaceutical compositions containing the same and methods of using such compounds for the treatment of cancer.

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.

HETEROCYCLIC UREA COMPOUNDS

The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture

ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The disclosure concerns heterobicyclic compounds of general formula (I) and acid addition salts, hydrates and solvates thereof, as well as enantiomers, diastereoisomers and mixtures thereof. Methods for preparing the compounds, pharmaceutical compositions, and methods of treatment also are disclosed.

PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS

The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.